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Abstract
According to the Center of Disease Control and Prevention (CDC) database the total
number of deaths due to opioid overdose from 1999 through 2018 was 840,629. Given the
alarming nature of these statistics, patients who requested prescription for opioids became targets
of suspicion and possible accusation of maladaptive behavior. Patients with sickle cell disease
(SCD) were often not exempt from such accusations and became guilty by association. In order
to clarify the effect of opioids on the mortality of patients with SCD, the mortality rates for
children and adults with SCD were investigated using the CDC Wide-ranging Online Data for
Epidemiologic Research (WONDER) Multiple Cause of Death database which is based on all
the death certificates issued in the United States from 1999-2018. The data showed 15,765
patients with SCD died from 1999-2018. Only 348 patients with SCD died due to opioids. The
CDC database contains 27 categories of death based on ICD-10 codes in patients with SCD and
opioids were the 19th ranking cause of death. Surprisingly the most common causes of death of
patients with SCD included circulatory, infection, respiratory, genitourinary and vaso-occlusive
crises/acute chest syndrome disorders in decreasing frequency. The mean age of death of females
was 41.9 years and of males 39.3 years; p < 0.0001. Death due to SCD and death due to SCD
and opioids were highest in the Southern Region of the United States.
Introduction
Sickle pain is unique [1]. It can be acute, chronic, intermittent, recurrent, remittent or
persistent [1-5]. Physical sensation and emotion in sickle pain are intertwined in an unusually
complex manner that is specific to each person and affects behavior differently in different
patients and in different vaso-occlusive crisis (VOC). It is often described by some patients as: “a
migraine headache that affects all your body; it controls you, you have no control over it;
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toothache all over your body; it means pain and suffering, etc. etc.” [6].
Up until the 1970s, sickle cell disease (SCD) was primarily a disease of children with
relatively few adults affected. With time, however, the number of adults with SCD increased
gradually and frequent visits to the emergency department (ED) and/or hospital admissions to
treat severe pain due to VOCs became a status quo of the disease. Opioids were the best and the
most common analgesics used to treat pain for the majority of patients. Issues associated with
transition of care from pediatrics to adult care, race, education, insurance coverage and
disparities conspired with the use of opioids to create a negative picture about adult patients with
SCD. Descriptors about most patients with SCD as “frequent flyers,” addicts, opioid abusers,
maladaptive behavior, etc. emerged [6, 7].

The emergence of the opioid epidemic in the United States worsened the situation for
patients with SCD who need opioids to alleviate their pain. The opioid epidemic was a
justification for some providers to restrict the use of opioids to treat sickle cell pain and, possibly
find alternatives to opioids. NSAIDS are often considered as an alternative but these are not as
effective in adults as in children [6]. Moreover the systemic side effects of NSAIDS including
renal failure, gastrointestinal bleeding, cardiovascular complications, etc. are worse than the
systemic complications of opioids [6]. Cannabinoids and Kratom failed as replacements to
opioids to date [8, 9]. Moreover, recent reports found that death due to opioids in SCD is much
lower than in other conditions and the use of opioids by patients with SCD was constant over the
years [10, 11]. The purpose of this study is to show that opioids are a minor cause of death in
patients with SCD. The complications of SCD itself rather than the opioids are the major cause
of death.
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Methods
Data were collected using the Center of Disease Control and Prevention (CDC) Wideranging Online Data for Epidemiologic Research (WONDER) Multiple Cause of Death database
which is based on all the death certificates issued in the United states from 1999-2018 [12-14].
Causes of death are based on the ICD-10 codes indicated on the death certificate. In order to
determine the number of deaths due to SCD and opioids, searches were conducted on the CDC’s
WONDER Multiple Cause of Death database using the ICD-10 codes for SCD and the same
ICD-10 codes that the CDC uses at the end of every year to report the nationwide number of
deaths due to opioids [12-14]. The CDC’s WONDER Multiple Cause of Death database enables
the user to run searches using multiple causes of death. The database allows the user to
determine the number of deaths per year, by gender, census region and other various factors.
The codes used to determine death due to SCD were as follows:
D57.0 Sickle-cell anaemia with crisis
D57.1 Sickle-cell anaemia without crisis
D57.2 Double heterozygous sickling disorders
D57.8 Other sickle-cell disorders

The codes used to determine number of deaths due to opioids, as used by the CDC to
determine nationwide rates, were the following:
T40.0
T40.1
T40.2
T40.3
T40.4
T40.6
X40
X41

Opium
Heroin
Other opioids
Methadone
Other synthetic narcotics
Other and unspecified narcotics
Accidental poisoning by and exposure to nonopioid analgesics,
antipyretics and antirheumatics
Accidental poisoning by and exposure to antiepileptic, sedative-hypnotic,
antiparkinsonism and psychotropic drugs, not classified elsewhere
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X42
X43
X44
X60
X61

X62
X63
X64
X85
Y10
Y11

Y12
Y13
Y14

Accidental poisoning by and exposure to narcotics and psychodysleptics
(hallucinogens), not elsewhere classified
Accidental poisoning by and exposure to other drugs acting on the
autonomic nervous system
Accidental poisoning by and exposure to other and unspecified drugs,
medicants and biological substances
Intentional self-poisoning by and exposure to nonopioid analgesics,
antipyretics and antirheumatics
Intentional self-poisoning by and exposure to antiepileptic, sedativehypnotic, antiparkinsonism and psychotropic drugs, not classified
elsewhere
Intentional self-poisoning by and exposure to narcotics and
psychodysleptics (hallucinogens), not elsewhere classified
Intentional self-poisoning by and exposure to other drugs acting on the
autonomic nervous system
Intentional self-poisoning by and exposure to other and unspecified drugs,
medicants and biological substances
Assault by drugs, medicaments and biological substances
Poisoning by and exposure to nonopioid analgesics, antipyretics and
antirheumatics, undetermined intent
Poisoning by and exposure to antiepileptic, sedative-hypnotic,
antiparkinsonism and psychotropic drugs, not classified elsewhere,
undetermined intent
Poisoning by and exposure to narcotics and psychodysleptics
(hallucinogens), not elsewhere classified, undetermined intent
Poisoning by and exposure to other drugs acting on the autonomic nervous
system, undetermined intent
Poisoning by and exposure to other and unspecified drugs, medicants and
biological substances, undetermined intent

Many of the ICD-10 codes used by the CDC to determine the number of deaths due to
opioids did not always include opioids. Reasons as to why these particular codes are used by the
CDC were not of primary concern. The greater concern was to show that although the number of
deaths due to opioids is quite high nationwide according to the CDC [12-14], that is not the case
with patients with SCD. That is why searches pertaining to opioid deaths were conducted using
the exact codes used by the CDC in addition to the ICD-10 codes for SCD.
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Once the data were collected, basic statistics were calculated using Systat 13 to determine
the mean and standard deviation. Figures indicating a scatter pattern reflect p values determined
by regression analysis. P values indicated in the tables were calculated using the t score.
Results
According to the CDC WONDER Multiple Cause of Death database 840,629 patients in
the general population died from 1999 through 2018 due to opioid overdose. However, only 348
patients with SCD died of opioid overdose during the same time (p < 0.0001) [14]. In addition,
regression analysis of the data showed that the number of deaths of patients with SCD due to
opioid overdose did not change significantly from 1999 through 2018 [11].
The CDC WONDER Multiple Cause of Death database contains 27 categories of death
based on ICD-10 codes in patients with SCD arranged in decreasing order of frequency as shown
in Table 1 with opioids ranking at number 19. These data indicate that the most common causes
of death include the circulatory system followed by infection including sepsis, etc. Figure 1 is a
bar diagram showing the five most common causes of death and includes death due to opioids
for comparison.
The extensive CDC WONDER Multiple Cause of Death database allowed the
exploration of the determinants of mortality of patients with SCD including sex, age,
geographical location and etiology. The CDC data did not differentiate gender from sex. The
relation between age/sex and mortality is summarized in Table 2. Specifically, during the 20
years of collected data by the CDC, the total number of women with SCD who died was greater
than the total number of men: 8010 women v 7755 men (p < 0.0001). This difference seems to be
primarily due to the difference in patients > 50 years old. On the other hand, the mean age of the
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total number of deaths due to opioids is significantly lower than that for patients who died from
other causes: 35.9 years v 40.7 years; p < 0.0001. The same is true for females and males (Table
2).
The number of death of patients with SCD due to opioid use is highest in the South and
similar in the Northeast, Midwest and West regions of the United States. This pattern is similar
to death due to opioids in non-SCD patients.
Discussion
The present study describes the age, gender, region and causes of death of patients with
SCD using the CDC WONDER Multiple Cause of Death database as described in Methods
above.

Life expectancy and risk factors for early death of patients with SCD have been an
important subject that was addressed by several studies over the years. Most important among
these is the study by Platt et al[15] indicating that 78% of deaths had pain, acute chest syndrome
(ACS), or both and 22 percent had stroke. Opioids as a cause of death in that study were not
mentioned since the opioid epidemic was not an issue at that time. Since then, the common
causes of death of patients with SCD included infection, stroke, ACS, sudden death and organ
failure [16-19]. Opioids were not mentioned in these studies as a cause of death. More recently,
a comprehensive study by Lubeck et al [20] estimated life expectancy and income of patients
with SCD but, opioids were not mentioned in that study as well. A recent report mentioned that
patients with SCD are falsely accused of being part of the opioid epidemic [10]. In addition,
opioid use by patients with SCD was stable over time both in the commercial and Medicaid
cohorts [11].
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It must be emphasized that this study is not an advocate for the use of high doses of
opioids to treat sickle cell pain in general and pain associated with VOCs in particular. It is a
recommendation for the adequate treatment of sickle cell pain that offers pain relief and better
quality of life. This can be achieved by following the NIH guidelines for the treatment of sickle
cell pain. These guidelines specifically state that the provider should determine the analgesic
selection based on pain assessment, associated signs and symptoms, outpatient analgesic use and
past experience with side effects [21, 22]. This almost always includes the use of the most
appropriate opioid and its dose for the patient in question. In addition, a written treatment plan
signed by the patient and the provider must be established. The plan should include the
performance of random urine drug screening.
Comparing the age at death of this study to previous studies raises several questions.
Overall, the mean age at death of this study is 40.7 years with 41.9 for females and 39.3 for
males (Table 2). Similarly, Lanzkron et al reported the mean age at death of females was 36.9
years and 33.4 years for males [19]. For patients older than 50 years the age at death for females
was 61.1 years and 59.8 years for males (Table 2).
Of concern, is the mean age at death of patients who died due to opioids is younger than
the mean age at death due to other causes than opioids: 35.9 vs 40.7 (p < 0.0001) This is also true
for both females an males (Table 2). Whether this is due to opioids or complications of SCD is
unknown.
The clinical manifestations and the causes of death in patients with SCD have changed
over the years. As mentioned above, the major cause of death in the 1990s was VOCs and ACS.
Currently, VOCs and ACS rank number 5 after circulatory, infection, respiratory and
genitourinary complications (Figure 1). Similarly, infection was the most common cause of death
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of patients with SCD in Rio de Janeiro, Brazil [23]. Nevertheless, VOCs continue to be the major
cause of admissions to the ED and hospital. Thus, figuratively speaking, the VOC seems to be
the tip of the iceberg of the complicated hidden pathophysiologic events of the disease. The
silent mediators of inflammation originate from activated leukocytes, mast cells, macrophages,
platelets and endothelial cells that release histamine, serotonin, prostaglandins, leukotrienes,
chemokines, cytokines, platelet activating factor and reactive oxygen species among others. As
the concentration of these mediators increase gradually, a point is reached where they cause
further tissue damage leading to the precipitation of a new VOC or reactivating a previously
resolving VOC. Accordingly, a vicious cycle of recurring VOCs is created and associated with
gradual increase in inflammation and organ damage.
The current study has some limitations. The first pertains to the fact the data were based
on information included in the death certificates. This may be inaccurate and is usually based on
what happened during the 24 hours before death. The second limitation is that the data were not
categorized according to the type of SCD. The CDC data lumped all types of SCD together.
Individuals with sickle cell trait were excluded. Patients with hemoglobin (Hb) SC disease are
known to have better survival than patients with sickle cell anemia (SSA). In the study by Platt et
al [15] the median survival of males with Hb SC was 60 years and for females was 68 years. In
this study, the mean survival of males with all types of SCD excluding sickle cell trait was 39.3
years and for females was 41.9 as shown in Table 2. On the other hand, in this study, the mean
age of survival for males who died due to opioids was 36.0 years and for females was 35.8 years
(Table 2). Given that patients with Hb SC have better survival, the survival of patients with SSA
in this study would be less than shown in Table 2. In addition, a recent study from Brazil
reviewed survival data of patients with SCD from 2000 to 2018 and found the median survival of
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9812 patients to be 29.5 years with the median survival of 4782 males equals 27.5 years and of
5030 females equals 31.0 years [24]. Similarly, another Brazilian study from a single institution
showed that among 1676 patients with SSA the median age at death was 28.98 years for men and
34.02 years for women [23].
Thus, it seems there has been no improvement in the survival of patients with SSA in
both males and females with and without opioid use in the present study compared with Platt’s et
al study [15]. Hopefully, the recent advent of disease modifying therapies including L-glutamine,
crizanlizumab and voxelotor as well as advances in stem cell transplantation and gene therapy
will improve survival of patients with SCD in the near future.
In summary, this study shows that survival of patients with SCD is gender, age and
region dependent. Opioids were not a major cause of death. The overall mean age of death of
females and males was less than that reported by Platt et al in 1994 [15]. Females who died due
to SCD live longer than males in the > 50 years age group but not in patients with SCD who died
due to opioids in the same > 50 years age group. Mortality of patients with SCD was highest in
the southern region of the US. The most common cause of death was not VOC/ACS but the
circulatory and infection/sepsis complications. More prospective studies are needed to
characterize the changing clinical landscape of SCD.

Legend to the Figures:
Figure 1:

Number of Causes of Deaths of Patients with Sickle Cell Disease from 19992018. Centers for Disease Control and Prevention. CDC WONDER Multiple
Cause of Death database, 1999-2018. 2020.
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Table 1
Causes of Death of Patients with Sickle Cell Disease Arranged in Decreasing
Order of Frequency 1999-2018

Cause of Death
1

Circulatory system (including PAH and HF)

Number of
Deaths
8643

2

Infection (including Sepsis and Pneumonia)

3585

3

Respiratory conditions (excluding Pneumonia)

2935

4

Genitourinary system (including CKD)

2836

5

Infection (including Sepsis)

2756

6

2519

7

Symptoms, signs and abnormal clinical and laboratory
findings not classified
Acute Chest Syndrome/Vaso-occlusive crises

8

Digestive system diseases

2038

9

Endocrine, nutritional and metabolic diseases

1778

2448

10 Heart Failure

1211

11 Pulmonary Hypertension

1034

12 Diseases of the blood and blood-forming organs and
certain disorders involving the immune mechanism
13 Injury, poisoning and certain other consequences of
external causes
14 Mental and behavioral disorders

978

15 Pneumonia

829

16 Nervous system diseases

666

17 Other external causes of morbidity and mortality

371

886
838

Gender
4439 (F)
4204 (M)
1875 (F)
1710 (M)
1520 (F)
1415 (M)
1416 (F)
1420 (M)
1452 (F)
1304 (M)
1316 (F)
1203 (M)
1210 (F)
1238 (M)
993 (F)
1105 (M)
972 (F)
806 (M)
649 (F)
562 (M)
623 (F)
411 (M)
522 (F)
456 (M)
400 (F)
486 (M)
363 (F)
475 (M)
423 (F)
406 (M)
350 (F)
316 (M)
189 (F)
182 (M)

% of Total
Deaths
54.8
22.7
18.6
18.0
17.5
16.0
15.5
12.9
11.3
7.7
6.6
6.2
5.6
5.3
5.3
4.2
2.4
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18 Musculoskeletal system (including Osteoporosis and
osteopenia)
19 Opioids

369

222 (F)
147 (M)
348
147 (F)
201 (M)
20 All Accidents
280
126 (F)
154 (M)
21 Skin and subcutaneous tissue diseases
115
67 (F)
48 (M)
22 Congenital malformations, deformations and
92
42 (F)
chromosomal abnormalities
50 (M)
23 Conditions originating in the perinatal period
24
9 (F)
15 (M)
24 Pregnancy, childbirth and the puerperium
17
17 (F)
0 (M)
25 Eye and adnexa diseases
14
6 (F)
8 (M)
26 Suicide
12
3 (F)
9 (M)
27 Ear and mastoid process diseases
10
6 (F)
4 (M)
CKD = Chronic kidney disease; HF = Heart failure; PAH = Pulmonary arterial hypertension; SCD =
Sickle cell disease
Reference: Centers for Disease Control and Prevention. CDC WONDER Multiple cause of Death
database, 1999-2018.

2.3
2.2
1.8
0.7
0.6
0.2
0.1
0.1
0.1
0.1
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Table 2
Mean Age of Death of Patients with SCD and of Patients with SCD Who Died Due to Opioids

Number of Deaths of Patients with SCD
Age Group (n) Mean Age (n) Mean Age (n) Mean Age
Total (yrs)
Females (yrs) Males (yrs)
*
0-18
(1136) 9.4
(524) 9.5*
(612) 9.3*
a
19-35
(4912) 27.9
(2322) 28.1* (2590) 27.7b
36-50
(5400) 43.0* (2736) 43.1* (2664) 42.8b
> 50
(4317) 60.5c
(2428) 61.1c
(1889) 59.8 c
0-100
(15765) 40.7 d (8010) 41.9 d (7755) 39.3 d
n = Number of patients; SCD = Sickle cell disease; yrs = Years

Number of Deaths of Patients with SCD Who
Died Due to Opioids
(n) Mean Age (n) Mean Age
(n) Mean Age
Total (yrs)
Females (yrs)
Males (yrs)
(12) 12.2*
(4)12.0*
(8) 12.3*
a
(167) 28.5
(68) 27.5*
(99) 29.3b
(137) 42.0*
(62) 42.1*
(75) 42.0b
(32) 57.6 c
(13) 56.6 c
(19) 58.3 c
(348) 35.9 d
(147) 35.8 d
(201) 36.0 d

* Not significant; a = p < 0.01; b = p < 0.05; c = p < 0.0001; d = p <0.0001

Reference: Centers for Disease Control and Prevention. CDC WONDER Multiple cause of Death database, 1999-2018.
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